ESSA Pharma R&D spend
ESSA Pharma Inc. · EPIX (NASDAQ) · Vancouver, BC · Pharmaceuticals
Latest R&D (CAD)
$29.0M
Period ended 2024-09-30
Revenue (CAD)
—
— of revenue
R&D by fiscal period
2024
$29.0M
2023
$28.8M
2022
$31.8M
2021
$30.4M
2020
$16.3M
2019
$8.9M
2018
$6.3M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2024-09-30 | $29,049,108 | — | $21,206,824 USD | 10-K | SEC EDGAR |
| 2023-09-30 | $28,779,019 | — | $21,322,530 USD | 10-K | SEC EDGAR |
| 2022-09-30 | $31,771,560 | — | $24,415,246 USD | 10-K | SEC EDGAR |
| 2021-09-30 | $30,408,643 | — | $24,258,989 USD | 10-K | SEC EDGAR |
| 2020-09-30 | $16,293,816 | — | $12,145,968 USD | 10-K | SEC EDGAR |
| 2019-09-30 | $8,885,233 | — | $6,696,234 USD | 10-K | SEC EDGAR |
| 2018-09-30 | $6,314,380 | — | $4,873,335 USD | 20-F | SEC EDGAR |